 H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc NASDAQ: TPST with a Buy rating and 51 price target, seeing an upside potential of over 100. A strategic portfolio of targeted therapies in oncology gives Tempest an edge, analyst Joseph Pantginis tells investors in a research note. 